ML385

Catalog No.S8790 Batch:S879004

Print

Technical Data

Formula

C29H25N3O4S
Molecular Weight 511.59 CAS No. 846557-71-9
Solubility (25°C)* In vitro DMSO 100 mg/mL (195.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
10% DMSO 40% PEG 300 5%Tween80  45%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 3.000mg/ml (5.86mM) Taking the 1 mL working solution as an example, add 100 μL of 30 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ML385 is a novel and specific NRF2 inhibitor with an IC50 of 1.9 μM. It inhibits the downstream target gene expression of NRF2. NRF2 regulates the activity of several ferroptosis and lipid peroxidation-related proteins.
Targets
Ferroptosis [3] Nrf2 [1]
1.9 μM
In vitro

ML385 shows anti-tumor activity in NSCLC (subcutaneous and orthotopic NSCLC models) both as a single agent and in combination. The PK profile tested in CD-1 mice shows that ML385 has a half-life (t1/2 = 2.82 h) after IP injection (30 mg/kg)[1]. ML385 could alleviate the pancreatic injury[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    A549 cells

  • Concentrations

    5 μM

  • Incubation Time

    24, 48 and 72 h

  • Method

    --
Animal Study:

[1]
  • Animal Models

    male CD-1 mice

  • Dosages

    30 mg/kg

  • Administration

    i.p.

References

  • https://www.ncbi.nlm.nih.gov/pubmed/27552339
  • https://www.hindawi.com/journals/omcl/2018/7161592/
  • https://pubmed.ncbi.nlm.nih.gov/32907551/

Selleck's ML385 has been cited by 145 publications

Growth differentiation factor 15 aggravates sepsis-induced cognitive and memory impairments by promoting microglial inflammatory responses and phagocytosis [ J Neuroinflammation, 2025, 22(1):44] PubMed: 39985040
Preventive hyperbaric oxygen therapy improves acute graft-versus-host disease by activating the Nrf2/HO-1 pathway [ Front Immunol, 2025, 16:1529176] PubMed: 40083556
SAMSN1 causes sepsis immunosuppression by inducing macrophages to express coinhibitory molecules that cause T-cell exhaustion via KEAP1-NRF2 signaling [ Chin Med J (Engl), 2025, 138(13):1607-1620] PubMed: 40293473
Hyperoxia-activated Nrf2 regulates ferroptosis in intestinal epithelial cells and intervenes in inflammatory reaction through COX-2/PGE2/EP2 pathway [ Mol Med, 2025, 31(1):1] PubMed: 39754066
Ligustrazine hydrochloride Prevents Ferroptosis by Activating the NRF2 Signaling Pathway in a High-Altitude Cerebral Edema Rat Model [ Int J Mol Sci, 2025, 26(3)1110] PubMed: 39940878
Acupuncture attenuates myocardial ischemia/reperfusion injury-induced ferroptosis via the Nrf2/HO-1 pathway [ Chin Med, 2025, 20(1):61] PubMed: 40346679
Vaccarin Ameliorates Renal Fibrosis by Inhibiting Ferroptosis via Nrf2/SLC7A11/GPX4 Signaling Pathway [ Drug Des Devel Ther, 2025, 19:1609-1626] PubMed: 40066086
Acute heat stress upregulates Akr1b3 through Nrf-2 to increase endogenous fructose leading to kidney injury [ J Biol Chem, 2025, 301(2):108121] PubMed: 39710324
TFEB-dependent autophagy-lysosomal pathway is required for NRF2-driven antioxidative action in obstructive sleep apnea-induced neuronal injury [ Cell Signal, 2025, 128:111630] PubMed: 39875050
The synergistic protective effects of paeoniflorin and β-ecdysterone against cardiac hypertrophy through suppressing oxidative stress and ferroptosis [ Cell Signal, 2025, 125:111509] PubMed: 39549820

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.